Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

Gastroenterology - Tập 158 - Trang 1851-1864 - 2020
Thomas G. Cotter1, Mary Rinella2
1Division of Gastroenterology and Hepatology, The University of Chicago Medicine, Chicago, Illinois
2Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Tài liệu tham khảo

Best, 1949, Liver damage produced by feeding alcohol or sugar and its prevention by choline, Br Med J, 2, 1002, 10.1136/bmj.2.4635.1001

Hanssen, 1936, Enlargement of the liver in diabetes mellitus, JAMA, 106, 914, 10.1001/jama.1936.02770110030011

Zelman, 1952, The liver in obesity, AMA Arch Intern Med, 90, 141, 10.1001/archinte.1952.00240080007002

Thaler, 1962, [The fatty liver and its pathogenetic relation to liver cirrhosis], Virchows Arch Pathol Anat Physiol Klin Med, 335, 180, 10.1007/BF02438705

Ludwig, 1980, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin Proc, 55, 434

Matteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8

Angulo, 2002, Nonalcoholic fatty liver disease, N Engl J Med, 346, 1221, 10.1056/NEJMra011775

Clark, 2002, Nonalcoholic fatty liver disease, Gastroenterology, 122, 1649, 10.1053/gast.2002.33573

Swinburn, 2011, The global obesity pandemic: shaped by global drivers and local environments, Lancet, 378, 804, 10.1016/S0140-6736(11)60813-1

Afshin, 2017, Health Effects of overweight and obesity in 195 countries over 25 years, N Engl J Med, 377, 13, 10.1056/NEJMoa1614362

Hales, 2017, Prevalence of obesity among adults and youth: United States, 2015–2016, NCHS Data Brief No. 288

Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367

Younossi, 2020, Epidemiology of chronic liver diseases in the USA in the past three decades, Gut, 69, 564, 10.1136/gutjnl-2019-318813

Kim, 2018, OPTN/SRTR 2016 annual data report: liver, Am J Transplant, 18, 172, 10.1111/ajt.14559

Younossi, 2019, Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin Gastroenterol Hepatol, 17, 748, 10.1016/j.cgh.2018.05.057

Haldar, 2019, Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study, J Hepatol, 71, 313, 10.1016/j.jhep.2019.04.011

Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431

Koehler, 2012, Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study, J Hepatol, 57, 1305, 10.1016/j.jhep.2012.07.028

Kagansky, 2004, Non-alcoholic fatty liver disease—a common and benign finding in octogenarian patients, Liver Int, 24, 588, 10.1111/j.1478-3231.2004.0969.x

Zelber-Sagi, 2006, Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures, Liver Int, 26, 856, 10.1111/j.1478-3231.2006.01311.x

Yang, 2014, Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis, Hepatology, 59, 1406, 10.1002/hep.26761

Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466

Allen, 2018, Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study, Hepatology, 67, 1726, 10.1002/hep.29546

Younossi, 2019, Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 69, 2672, 10.1002/hep.30251

Fleischman, 2014, NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis, World J Gastroenterol, 20, 4987, 10.3748/wjg.v20.i17.4987

Sayiner, 2016, Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world, Clin Liver Dis, 20, 205, 10.1016/j.cld.2015.10.001

Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109

Younossi, 2018, Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis, Hepatology, 68, 349, 10.1002/hep.29721

Palmer, 2013, Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent, Hepatology, 58, 966, 10.1002/hep.26440

Després, 2000, Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study, Arterioscler Thromb Vasc Biol, 20, 1932, 10.1161/01.ATV.20.8.1932

Sanyal, 2019, The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the Simtuzumab trials, Hepatology, 70, 1913, 10.1002/hep.30664

Kleiner, 2019, Association of histologic disease activity with progression of nonalcoholic fatty liver disease, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.12565

Liangpunsakul, 2012, What should we recommend to our patients with NAFLD regarding alcohol use?, Am J Gastroenterol, 107, 976, 10.1038/ajg.2012.20

Sanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002/hep.24376

Rehm, 2010, Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis, Drug Alcohol Rev, 29, 437, 10.1111/j.1465-3362.2009.00153.x

Becker, 1996, Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study, Hepatology, 23, 1025, 10.1002/hep.510230513

Bedogni, 2005, Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study, Hepatology, 42, 44, 10.1002/hep.20734

Ajmera, 2018, Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis, Clin Gastroenterol Hepatol, 16, 1511, 10.1016/j.cgh.2018.01.026

Kowdley, 2012, Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 55, 77, 10.1002/hep.24706

Regev, 2006, Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study, J Pediatr Gastroenterol Nutr, 43, S30, 10.1097/01.mpg.0000226387.56612.1e

Strnad, 2019, Heterozygous carriage of the alpha1-antitrypsin Pi∗Z variant increases the risk to develop liver cirrhosis, Gut, 68, 1099, 10.1136/gutjnl-2018-316228

Vuppalanchi, 2012, Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network, Hepatol Int, 6, 379, 10.1007/s12072-011-9277-8

Caldwell, 2009, NASH and cryptogenic cirrhosis: a histological analysis, Ann Hepatol, 8, 346, 10.1016/S1665-2681(19)31748-X

Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043

Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality, Hepatology, 53, 1874, 10.1002/hep.24268

Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085

Angulo, 1999, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 30, 1356, 10.1002/hep.510300604

Noureddin, 2013, Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients, Hepatology, 58, 1644, 10.1002/hep.26465

Bedogni, 2007, Incidence and natural course of fatty liver in the general population: the Dionysos study, Hepatology, 46, 1387, 10.1002/hep.21827

Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623

Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x

Dam-Larsen, 2004, Long term prognosis of fatty liver: risk of chronic liver disease and death, Gut, 53, 750, 10.1136/gut.2003.019984

Rafiq, 2009, Long-term follow-up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 7, 234, 10.1016/j.cgh.2008.11.005

Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368

Hagström, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027

Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 37, 917, 10.1053/jhep.2003.50161

Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary, Crit Pathw Cardiol, 4, 198, 10.1097/00132577-200512000-00018

Targher, 2007, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients, Diabetes Care, 30, 1212, 10.2337/dc06-2247

Bellentani, 2010, Epidemiology of non-alcoholic fatty liver disease, Dig Dis, 28, 155, 10.1159/000282080

VanWagner, 2016, Extrahepatic manifestations of nonalcoholic fatty liver disease, Curr Hepatol Rep, 15, 75, 10.1007/s11901-016-0295-9

Sanyal, 2001, Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities, Gastroenterology, 120, 1183, 10.1053/gast.2001.23256

Neuschwander-Tetri, 2010, Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease, Hepatology, 52, 913, 10.1002/hep.23784

Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002/hep.24127

Stepanova, 2010, Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study, Gut, 59, 1410, 10.1136/gut.2010.213553

Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9

Ballestri, 2016, Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis, J Gastroenterol Hepatol, 31, 936, 10.1111/jgh.13264

Neuschwander-Tetri, 2012, Fatty liver and nonalcoholic steatohepatitis, 106

Sasaki, 2014, Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments, Front Endocrinol (Lausanne), 5, 164, 10.3389/fendo.2014.00164

Subichin, 2015, Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery, Surg Obes Relat Dis, 11, 137, 10.1016/j.soard.2014.06.015

Park, 2008, Visceral adipose tissue area is an independent risk factor for hepatic steatosis, J Gastroenterol Hepatol, 23, 900, 10.1111/j.1440-1746.2007.05212.x

Hamaguchi, 2007, The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation, Am J Gastroenterol, 102, 2708, 10.1111/j.1572-0241.2007.01526.x

van der Poorten, 2008, Visceral fat: a key mediator of steatohepatitis in metabolic liver disease, Hepatology, 48, 449, 10.1002/hep.22350

Kim, 2016, Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 14, 132, 10.1016/j.cgh.2015.07.024

Yu, 2015, Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease, Medicine (Baltimore), 94, e2159, 10.1097/MD.0000000000002159

2004, Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies, Lancet, 363, 157, 10.1016/S0140-6736(03)15268-3

McLaughlin, 2011, Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity, J Clin Endocrinol Metab, 96, E1756, 10.1210/jc.2011-0615

Chitturi, 2002, NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome, Hepatology, 35, 373, 10.1053/jhep.2002.30692

Leite, 2009, Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus, Liver Int, 29, 113, 10.1111/j.1478-3231.2008.01718.x

Prashanth, 2009, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus, J Assoc Physicians India, 57, 205

Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021

Browning, 2006, Statins and hepatic steatosis: perspectives from the Dallas Heart Study, Hepatology, 44, 466, 10.1002/hep.21248

Chang, 2013, Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population, Am J Gastroenterol, 108, 1861, 10.1038/ajg.2013.349

Sung, 2013, Resolution of fatty liver and risk of incident diabetes, J Clin Endocrinol Metab, 98, 3637, 10.1210/jc.2013-1519

Fujimoto, 1994, The visceral adiposity syndrome in Japanese-American men, Obes Res, 2, 364, 10.1002/j.1550-8528.1994.tb00076.x

Du, 2016, Lipid phenotypes in patients with nonalcoholic fatty liver disease, Metabolism, 65, 1391, 10.1016/j.metabol.2016.06.006

Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621

Siddiqui, 2015, Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile, Clin Gastroenterol Hepatol, 13, 1000, 10.1016/j.cgh.2014.10.008

Fabbrini, 2008, Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease, Gastroenterology, 134, 424, 10.1053/j.gastro.2007.11.038

Adiels, 2008, Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome, Arterioscler Thromb Vasc Biol, 28, 1225, 10.1161/ATVBAHA.107.160192

Ryoo, 2014, Clinical association between non-alcoholic fatty liver disease and the development of hypertension, J Gastroenterol Hepatol, 29, 1926, 10.1111/jgh.12643

Sung, 2014, Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension, J Hepatol, 60, 1040, 10.1016/j.jhep.2014.01.009

Yki-Järvinen, 2014, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, 2, 901, 10.1016/S2213-8587(14)70032-4

Kotronen, 2008, Fatty liver: a novel component of the metabolic syndrome, Arterioscler Thromb Vasc Biol, 28, 27, 10.1161/ATVBAHA.107.147538

Li, 2019, Extrahepatic manifestations of nonalcoholic fatty liver disease, Gut Liver

Adams, 2004, Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction, Hepatology, 39, 909, 10.1002/hep.20140

Targher, 2017, Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease, Nat Rev Nephrol, 13, 297, 10.1038/nrneph.2017.16

Park, 2019, Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study, J Intern Med, 286, 711, 10.1111/joim.12964

Singal, 2014, Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology, Transplantation, 98, 216, 10.1097/TP.0000000000000048

Rotman, 2010, The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease, Hepatology, 52, 894, 10.1002/hep.23759

Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283

Liu, 2014, Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, J Hepatol, 61, 75, 10.1016/j.jhep.2014.02.030

Krawczyk, 2015, HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance, J Hepatol, 62, 980, 10.1016/j.jhep.2014.10.048

Younossi, 2012, Nonalcoholic fatty liver disease in lean individuals in the United States, Medicine (Baltimore), 91, 319, 10.1097/MD.0b013e3182779d49

Speliotes, 2010, PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease, Hepatology, 52, 904, 10.1002/hep.23768

Valenti, 2010, Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 51, 1209, 10.1002/hep.23622

Lallukka, 2013, Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3, Diabetologia, 56, 886, 10.1007/s00125-013-2829-9

Younossi, 2019, Non-alcoholic fatty liver disease—a global public health perspective, J Hepatol, 70, 531, 10.1016/j.jhep.2018.10.033

Su, 2019, Role of HSD17B13 in the liver physiology and pathophysiology, Mol Cell Endocrinol, 489, 119, 10.1016/j.mce.2018.10.014

Abul-Husn, 2018, A protein-truncating HSD17B13 variant and protection from chronic liver disease, N Engl J Med, 378, 1096, 10.1056/NEJMoa1712191

Basyte-Bacevice, 2019, TM6SF2 and MBOAT7 gene variants in liver fibrosis and cirrhosis, Int J Mol Sci, 20, 10.3390/ijms20061277

Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014

Liu, 2019, Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis, Sci Rep, 9, 11124, 10.1038/s41598-019-47687-3

Targher, 2010, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease, N Engl J Med, 363, 1341, 10.1056/NEJMra0912063

VanWagner, 2015, Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study, Hepatology, 62, 773, 10.1002/hep.27869

Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013

Younossi, 2016, Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality, Gastroenterology, 150, 1778, 10.1053/j.gastro.2016.03.005

Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034

Adams, 2017, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut, 66, 1138, 10.1136/gutjnl-2017-313884

Yang, 2017, Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: propensity score matching analysis, PLoS One, 12

Hamaguchi, 2019, Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study, BMJ Open Gastroenterol, 6, 10.1136/bmjgast-2019-000295

Cho, 2019, Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm, Liver Int, 39, 1722, 10.1111/liv.14163

Mohamad, 2016, Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis, Hepatol Int, 10, 632, 10.1007/s12072-015-9679-0

Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701

Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173

Rinella, 2019, Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD, Hepatology, 71, 823, 10.1016/j.jhep.2019.04.019

Kleiner, 2015, Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists, Gastroenterology, 149, 1305, 10.1053/j.gastro.2015.09.015

Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084

Chen, 2016, Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C, Medicine (Baltimore), 95

Younossi, 1998, Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations, Mod Pathol, 11, 560

Bohte, 2011, The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis, Eur Radiol, 21, 87, 10.1007/s00330-010-1905-5

Hannah, 2016, Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 64, 2234, 10.1002/hep.28699

Mikolasevic, 2016, Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease—where do we stand?, World J Gastroenterol, 22, 7236, 10.3748/wjg.v22.i32.7236

McPherson, 2010, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease, Gut, 59, 1265, 10.1136/gut.2010.216077

McPherson, 2017, Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis, Am J Gastroenterol, 112, 740, 10.1038/ajg.2016.453

Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496

Shah, 2009, Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 1104, 10.1016/j.cgh.2009.05.033

Anstee, 2019, Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR Trials, Hepatology, 70, 1521, 10.1002/hep.30842

Newsome, 2020, FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study, Lancet Gastroenterol Hepatol, 5, 362, 10.1016/S2468-1253(19)30383-8

Boyle, 2017, Development and validation of the collagen neo-epitope biomarker pro-C3 “FIB-C3 Score” for detection and staging of advanced non- alcoholic fatty liver disease in a large international multi-centre patient cohort, Hepatology, 66, 54A

Hanf, 2018, NIS4 for detection of active NASH (NAS≥4) and significant fibrosis (F≥2) in 714 patients at risk of NASH: diagnostic metrics are not affected by age, gender, type 2 diabetes or obesity, Hepatology, 68, 89A

Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers, Hepatology, 47, 455, 10.1002/hep.21984

Mayo, 2018, Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts, Hepatol Commun, 2, 807, 10.1002/hep4.1188

Hoang, 2019, Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease, Sci Rep, 9, 12541, 10.1038/s41598-019-48746-5

Castera, 2019, Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1264, 10.1053/j.gastro.2018.12.036

Sandrin, 2003, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001

Boursier, 2016, Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease, J Hepatol, 65, 570, 10.1016/j.jhep.2016.04.023

Tapper, 2016, The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 111, 677, 10.1038/ajg.2016.49

Imajo, 2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048

Vuppalanchi, 2018, Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease, Hepatology, 67, 134, 10.1002/hep.29489

Wong, 2019, Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease, Gut, 68, 2057, 10.1136/gutjnl-2018-317334

Siddiqui, 2019, Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, 156, 10.1016/j.cgh.2018.04.043

Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042

Chen, 2017, Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity, Radiology, 283, 418, 10.1148/radiol.2016160685

Loomba, 2016, Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study, Am J Gastroenterol, 111, 986, 10.1038/ajg.2016.65

Loomba, 2014, Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study, Hepatology, 60, 1920, 10.1002/hep.27362

Srinivasa Babu, 2016, Elastography in chronic liver disease: modalities, techniques, limitations, and future directions, Radiographics, 36, 1987, 10.1148/rg.2016160042

Harrison, 2020, Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study, J Hepatol, 72, 613, 10.1016/j.jhep.2019.10.023

Thông tin
Thông tin xuất bản

Gastroenterology

Tập 158

1851-1864

Thông tin tác giả